PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsEntasis Therapeutics
Entasis Therapeutics(ETTX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Loading
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Plot placeholder
Mock data
Subscribe for the real data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
XacduroSulbactam, Durlobactam2023-05-232033-2035
Respiratory tract infections
,
Urinary tract infections
,
Pneumococcal infections
,
Infectious pregnancy complications
,
Bacterial infections
,
Gonorrhea
,
Intraabdominal infections
,
Bacterial skin diseases
,
Escherichia coli infections
,
Soft tissue infections
,
Bacillary dysentery
,
Surgical wound infection
,
Staphylococcal infections
,
Bacterial endocarditis
,
Bacterial meningitis
,
Salmonella infections
,
Proteus infections
,
Acinetobacter infections
,
Listeriosis
,
Klebsiella infections
,
Meningococcal infections
,
Haemophilus infections
,
Human bites
,
Actinomycosis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Sulbactam
bacterial pneumonia
,
pneumonia
,
infections
,
communicable diseases
,
peritonitis
,
appendicitis
,
wound infection
,
cholecystitis
,
abdominal abscess
,
abscess
,
lung abscess
Zoliflodacin
healthy volunteers/patients
,
gonorrhea
Durlobactam
infections
,
renal insufficiency
,
healthy volunteers/patients
,
urinary tract infections
,
pyelonephritis
,
acinetobacter infections
,
ventilator-associated pneumonia
,
iatrogenic disease
,
bacteremia
ETX2514SUL
renal insufficiency
,
infections
,
urinary tract infections
,
pyelonephritis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use